A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments - Trial NCT06323928
Access comprehensive clinical trial information for NCT06323928 through Pure Global AI's free database. This Phase 2 trial is sponsored by H. Lundbeck A/S and is currently Recruiting. The study focuses on Migraine. Target enrollment is 498 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
H. Lundbeck A/S
Timeline & Enrollment
Phase 2
Apr 01, 2024
Sep 30, 2025
Primary Outcome
Change From Baseline in the Number of Monthly Migraine Days (MMDs)
Summary
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help
 prevent migraines. People who join this trial have already tried 2 to 4 other available
 medications to prevent their migraines, but these medications have not helped them.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06323928
Non-Device Trial